A Study of BION-1301 in Adults With IgA Nephropathy
IgA NephropathyImmunoglobulin A NephropathySafety and Efficacy of BION-1301 in Adults with IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA...
IgA NephropathyThis study will evaluate the efficacy and safety of HR19042 capsules compared to matching placebo for the treatment of primary IgA nephropathy, and explore the optimal dose for the treatment.
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)...
Lupus NephritisImmunoglobulin A Nephropathy2 moreThis is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age) with either LN or IgAN. The study will consist of an up to 6-week Screening Period, a 26-week blinded Initial Evaluation Period, a 24-week blinded Extended Treatment Period, and an Open-label Extension (OLE) Period of up to 2 years. Safety will be monitored throughout the study.
Steroids Therapy in IgA Nephropathy With Crescents
IgA NephropathyThis prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with crescents.
Atrasentan in Patients With Proteinuric Glomerular Diseases
IgA NephropathyFocal Segmental Glomerulosclerosis4 moreThe AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
Rituximab and RASi in Patients With IgAN
IgA NephropathyA study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.
An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases
Lupus NephritisImmunoglobulin A Nephropathy1 moreThe goal of this clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, or lupus-related kidney disease (lupus nephritis) to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
IgA NephropathyIgANThis is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease...
C3 GlomerulopathyIgA NephropathyThe purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy [C3G] and IgA Nephropathy [IgAN]). In Part 1 of the study, HVs will receive either one or two doses of ARO-C3 or placebo. In Part 2 of the study, adult patients with C3G/IgAN will receive 3 open-label doses of ARO-C3. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.
Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy
Primary IgA NephropathyThe study is being conducted to evaluate the efficacy, and safety of SHR - 2010 injection in patients with primary IgA nephropathy.